MOTS-c: evidence, safety and FDA status

MOTS-c drew attention after a 2015 mouse-and-cell study linked it to metabolism and insulin sensitivity ^[5]. The distinction for consumers is between a biological discovery and a tested treatment: an ongoing protocol exists, but its registry has no posted results ^[7]. FDA’s assessment identified missing human treatment evidence and product-characterization concerns ^[1].

MOTS-c is a small peptide your mitochondria make

Mitochondria, the energy-producing parts of your cells, carry their own small set of genes. In 2015, researchers reported a short stretch inside one mitochondrial gene, the 12S rRNA, that codes for a 16-amino-acid peptide. They named it MOTS-c and found that it regulates insulin sensitivity and metabolism, acting mainly on skeletal muscle ^[5].

MOTS-c isn't foreign to the body. FDA's briefing notes that it is present in the circulation of both humans and rodents ^[1], and it has been found in skeletal muscle, heart and brain. Products are marketed using free-base and acetate names; a label does not independently establish their identity or purity.

It wasn't the first peptide found this way. The discovery paper notes that an earlier mitochondrial peptide, humanin, had already been identified, which prompted the search for more ^[5]. MOTS-c was the next one, and its proposed mechanism runs through the folate cycle and purine production inside cells, ending in AMPK activation.

What MOTS-c did in mice: protection from diet-induced obesity and better late-life fitness

In the 2015 discovery paper, MOTS-c treatment in mice prevented insulin resistance caused by age and by a high-fat diet, and prevented diet-induced obesity ^[5]. Its cellular effects led to activation of AMPK, an energy-sensing enzyme that exercise also switches on. The paper identified skeletal muscle as its main target organ.

A 2021 study extended that to aging. MOTS-c improved physical performance in young, middle-aged and old mice, and intermittent treatment started late in life increased physical capacity and healthspan ^[6]. The mice were 2, 12 and 22 months old, roughly young adult, middle-aged and old for a mouse. MOTS-c also changed the activity of nuclear genes tied to metabolism and protein maintenance.

These experiments provide a preclinical rationale rather than a clinical promise. The discovery paper’s high-fat-diet experiment reported approximately 20% less weight gain over eight weeks, which is different from established fat loss in a person ^[1]. The MOTS-c fat-loss review separates those outcomes.

Human measurements and treatment trials answer different questions

The 2021 study also sampled humans. Exercise raised people's own MOTS-c, in muscle and in blood ^[6]. That is the source of the "exercise in a vial" pitch, and it is a measurement of the body's own peptide, not of an injection.

The reviewed sources do not establish clinical benefits from administered MOTS-c. FDA's 2026 review found no clinical studies providing pharmacokinetic data and no human exposure data to judge whether compounded products would be safe ^[1]. One trial is now under way: a randomized, placebo-controlled phase 2a study of MOTS-c in adults with prediabetes and overweight or obesity, run by a company in China, was registered in 2026 and is recruiting ^[7]. It has posted no results.

The current record estimates 120 participants and lists insulin sensitivity on an oral glucose-tolerance test at 12 weeks plus adverse events through 16 weeks as primary outcomes ^[7]. Its detailed description also names body weight and waist circumference, although those are absent from the structured outcome list. This discrepancy prevents a categorical claim that weight will not be measured. The primary completion estimate is February 2027 and full completion estimate May 2028; neither promises when results will appear.

Safety in humans is unknown

The current trial has no posted results and does not yet supply a dependable clinical safety estimate. FDA searched its adverse-event reporting system through March 2025 and found no reports for MOTS-c ^[1]. That is an absence of data, not evidence of safety.

FDA's stated concern is the product itself. Its safety-risks page says compounded MOTS-c may pose a significant risk of immune reactions for some routes, may have problems with impurities and characterization, and that FDA has not found human exposure data for any route ^[3]. Appetite and other side-effect questions are covered in is MOTS-c safe.

If someone offers you MOTS-c, these questions cut through the pitch:

• Which administered-MOTS-c study supports the claimed outcome? A protocol without results cannot establish it.
• What is the exact product and applicable authorization? A prescription or research label alone does not establish a compounding exemption or research authorization.
• How was identity and quality established? FDA’s assessment identified characterization and potential immune-reaction concerns.
• Are you subject to anti-doping rules? WADA names MOTS-c as prohibited at all times.

Approval, retail eligibility and research authorization differ

MOTS-c is not FDA-approved. FDA’s assessment reports no applicable USP or NF monograph for its free-base or acetate forms and neither is a component of an approved drug ^[1]. The current 503A regulation does not list it, and the reviewed interim categories do not establish ordinary retail bulk eligibility ^{[10] [4]}. An advisory recommendation is nonbinding and does not itself change that status.

The pending OIRA notice concerning certain peptides is under review, rather than issued policy with final terms ^[9]. Properly authorized clinical investigation has separate requirements for manufacturing information, nonclinical evidence, study oversight and eligibility ^[11]. A public trial registration does not establish every applicable authorization. The FDA-status review and legal-access review explain these distinctions.

The FDA meeting page names obesity and osteoporosis, while the briefing footnote explains that insufficient nomination information prevented formal evaluation of the nominated uses ^{[2] [1]}. Neither document establishes clinical benefit.

For other evidence questions, compare the pharmacokinetic evidence and time-to-benefit review. Related mitochondrial topics have separate evidence and legal records: see SS-31 and NAD+ rather than assuming a shared mechanism makes the products interchangeable.

MOTS-c is banned in sport as a metabolic modulator

WADA's 2026 Prohibited List names MOTS-c under S4.4.1, alongside AICAR, as an activator of the energy-sensing enzyme AMPK. Section S4 substances are prohibited at all times, in and out of competition ^[8].

Terms used on this page

• Mitochondrial-derived peptide: a peptide coded by the mitochondria's own DNA rather than the cell nucleus.
• AMPK: AMP-activated protein kinase, an enzyme that senses low cellular energy and is switched on by exercise.
• FAERS: FDA Adverse Event Reporting System, the database of side-effect reports sent to FDA.
• 503A bulks list: FDA's list of bulk ingredients licensed pharmacies may use to compound when no monograph or approved drug covers them.